Christopher Bowen - CME Chief MD
| CME Stock | USD 208.46 5.15 2.41% |
Executive
Christopher Bowen is Chief MD of CME Group
| Age | 63 |
| Address | 20 South Wacker Drive, Chicago, IL, United States, 60606 |
| Phone | 312 930 1000 |
| Web | https://www.cmegroup.com |
CME Management Efficiency
The company has Return on Asset of 0.0147 % which means that on every $100 spent on assets, it made $0.0147 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1173 %, implying that it generated $0.1173 on every 100 dollars invested. CME's management efficiency ratios could be used to measure how well CME manages its routine affairs as well as how well it operates its assets and liabilities. At present, CME's Return On Capital Employed is projected to increase slightly based on the last few years of reporting. The current year's Return On Assets is expected to grow to 0.03, whereas Return On Equity is forecasted to decline to 0.12. At present, CME's Non Currrent Assets Other are projected to decrease significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 99.6 B, whereas Other Assets are forecasted to decline to about 127.7 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Jennifer Hawes | Allegion PLC | 42 | |
| Douglas Foley | Intercontinental Exchange | 52 | |
| David Ilardi | Allegion PLC | 45 | |
| James Namkung | Intercontinental Exchange | 48 | |
| Stacie Sherer | Assurant | N/A | |
| Suzanne Shepherd | Assurant | N/A | |
| Mary ONeal | Intercontinental Exchange | N/A | |
| R Conner | Assurant | N/A | |
| Joseph III | Assurant | N/A | |
| Subhashish Sengupta | Assurant | N/A | |
| Nicholas Themelis | MarketAxess Holdings | 60 | |
| Richard Schiffman | MarketAxess Holdings | 58 | |
| Andrew Surdykowski | Intercontinental Exchange | 53 | |
| Kevin McPherson | MarketAxess Holdings | 53 | |
| Manuel Becerra | Assurant | 60 | |
| Scott Pintoff | MarketAxess Holdings | 53 | |
| Doshia Stewart | Allegion PLC | N/A | |
| Sean Moshier | Assurant | N/A | |
| Michael Cianciulli | MarketAxess Holdings | 36 | |
| Mary Sedarat | MarketAxess Holdings | N/A | |
| Joshua Pokrzywinski | Allegion PLC | N/A | |
Management Performance
| Return On Equity | 0.12 | ||||
| Return On Asset | 0.0147 |
CME Group Leadership Team
Elected by the shareholders, the CME's board of directors comprises two types of representatives: CME inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CME. The board's role is to monitor CME's management team and ensure that shareholders' interests are well served. CME's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CME's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jill Harley, Managing Director | ||
| Hilda Piell, Chief Human Resource Officer, Senior Managing Director | ||
| Terrence Duffy, Executive Chairman and President Member of Competitive Markets Advisory Council, Chairman of Executive Committee and Member of Strategic Steering Committee | ||
| Edward Gogol, Managing Solutions | ||
| Anita Liskey, Senior Communications | ||
| John Peschier, Managing Relations | ||
| Jason Weller, Managing Strategy | ||
| Sunil Cutinho, President - CME Clearing | ||
| Jack Tobin, Chief Accounting Officer, Managing Director | ||
| Julie Holzrichter, COO and Sr. Managing Director | ||
| Christopher Bowen, Chief MD | ||
| Kendal Vroman, Chief Officer | ||
| Michel Everaert, MD EMEA | ||
| Elizabeth Gisch, Managing Management | ||
| Jonathan Marcus, Senior Counsel | ||
| Derek Sammann, Senior Managing Director - Financial Products and Services | ||
| Eileen Keeve, Managing Devel | ||
| Sean Keating, MD Office | ||
| Kevin Lennon, Managing Estate | ||
| Julie Winkler, Senior Managing Director - Research and Product Development | ||
| Lynne Fitzpatrick, Chief Officer |
CME Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is CME a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.12 | ||||
| Return On Asset | 0.0147 | ||||
| Profit Margin | 0.57 % | ||||
| Operating Margin | 0.65 % | ||||
| Current Valuation | 77.37 B | ||||
| Shares Outstanding | 360.06 M | ||||
| Shares Owned By Insiders | 0.43 % | ||||
| Shares Owned By Institutions | 90.53 % | ||||
| Number Of Shares Shorted | 3.35 M | ||||
| Price To Earning | 32.83 X |
Pair Trading with CME
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CME position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CME will appreciate offsetting losses from the drop in the long position's value.Moving against CME Stock
| 0.47 | FG | FG Annuities Life | PairCorr |
The ability to find closely correlated positions to CME could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CME when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CME - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CME Group to buy it.
The correlation of CME is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CME moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CME Group moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CME can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CME Group. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Complementary Tools for CME Stock analysis
When running CME's price analysis, check to measure CME's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CME is operating at the current time. Most of CME's value examination focuses on studying past and present price action to predict the probability of CME's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CME's price. Additionally, you may evaluate how the addition of CME to your portfolios can decrease your overall portfolio volatility.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |
Is CME's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CME. If investors know CME will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CME listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.03) | Dividend Share 4.45 | Earnings Share 8.78 | Revenue Per Share 15.638 | Quarterly Revenue Growth 0.032 |
The market value of CME Group is measured differently than its book value, which is the value of CME that is recorded on the company's balance sheet. Investors also form their own opinion of CME's value that differs from its market value or its book value, called intrinsic value, which is CME's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CME's market value can be influenced by many factors that don't directly affect CME's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CME's value and its price as these two are different measures arrived at by different means. Investors typically determine if CME is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CME's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.